Taspoglutide
Sources
registry, as of 2016-07-28Stale
https://clinicaltrials.gov/study/NCT00823992
A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy. Overall status COMPLETED. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 305. Conditions Diabetes Mellitus Type 2. This 2 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to placebo in obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Patients will be randomized to receive taspoglutide (10mg sc once weekly for
ClinicalTrials.gov NCT00823992 protocol and results modules
publication, as of 2022-02-08Stale
https://pubmed.ncbi.nlm.nih.gov/34260945/
Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, carbohydrate metabolism, and appetite and is an important target for treatment of type 2 d
PMID 34260945